Development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations
This concept paper addresses the need for a specific guideline on the establishment of maximum residue limits (MRLs) for pharmacologically active nanoparticles, as well as on safety for veterinary medicinal products (VMPs) containing nanoparticles.
Keywords: Novel therapies, nano, safety, veterinary regulation, persistent nanoparticles, nano-toxicology, nanoparticles, nanotechnology, veterinary medicinal products issued from nanotechnologies
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
